Skip to main content

remestemcel-L

Generic: remestemcel-L·Brand: Ryoncil

remestemcel-L: 3 clinical trials tracked.

remestemcel-L evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about remestemcel-L, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Ulcerative Colitis
Clinical Trials (3)

Intermediate-size Expanded Access of Remestemcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

NCT04456439·MESO
No longer available
Expanded AccessMesoblast International Sàrl

A Phase IB/IIA Study of Remestemcel-L, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product, for the Treatment of Medically Refractory Ulcerative Colitis

NCT04543994·Phase 1/Phase 2
Terminated

Primary endpoint: Treatment related adverse events

InterventionalRandomizedsingle7 targetStarted 2020-11Completion 2023-111 site · United StatesThe Cleveland Clinic

A Phase IB/IIA Study of Remestemcel-L, an Ex-vivo Culture-expanded Adult Allogeneic Bone Marrow Derived Mesenchymal Stem Cell Product for the Treatment of Medically Refractory Crohn's Colitis

NCT04548583·Phase 1/Phase 2
Terminated

Primary endpoint: Treatment related adverse events

InterventionalRandomizedsingle7 targetStarted 2020-11Completion 2023-111 site · United StatesThe Cleveland Clinic